2020 - 2025
Louise Perrault
CAR-T therapies have transformed oncology, but their disruptive nature has also challenged traditional HTA and reimbursement systems worldwide.
Our latest industry trend report provides a comprehensive analysis of how twelve leading HTA agencies across North America, Europe, and Asia-Pacific have assessed CAR-T therapies between 2020 and 2025.
This report is a must-read for:
✔ Biopharma executives preparing CAR-T and advanced therapy launches
✔ Market access and HEOR leaders shaping global value strategies
✔ Policymakers and payers designing sustainable reimbursement models
Get Access